Skip to main content

Table 1 The potency and selectivity of all tested monoamine transporter inhibitors

From: Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

   IC50 (nM) of uptake inhibition Selectivity factor
Platelets SK-N-SH IC50 ratio
[3H]Serotonin [125I]MIBG [125I]MIBG
SSRIs Alaproclate 516 38 43420 1158
Citalopram 32 7.8 11940 1521
Fluvoxamine 30 9.3 2339 252
Fluoxetine 115 32 1270 40
Norfluoxetine 107 24 2760 115
Paroxetine 0.6 0.2 10 45
Sertraline 41 36 3301 91
TCAs Clomipramine 18 7 176 24
Imipramine 118 104 82 0.8
Desipramine 648 744 5 0.007
TeCA Maprotiline n.d. 1000–10,000 39 0.04–0.004
  1. Selective inhibition of 10−8 M [125I]MIBG or [3H]serotonin uptake by monoamine transporter inhibitors in human platelets or SK-N-SH neuroblastoma cells in vitro. Selectivity was expressed as the IC50 ratio of the MIBG uptake in SK-N-SH cells over that in platelets. SSRI Selective serotonin reuptake inhibitor; TCA Tricyclic antidepressant; TeCA Tetracyclic antidepressant